WhatPeptide

Demoxytocin

A synthetic oxytocin analog (1-deamino-oxytocin) with N-terminal Cys replaced by β-mercaptopropionic acid (Mpa), conferring greater enzymatic stability. Synthesized 1960, clinically introduced by Sandoz in 1971 as a buccal tablet. Approved in Italy, Czech Republic, and Poland (Sandopart/Odeax/Sandopral) for labor induction and lactation support. Never FDA-approved. Crystal structure solved by Wood et al. (Science 1986, PDB 1XY1/1XY2).

Moderate evidence Unregulated Hormone

Written by WhatPeptide Editorial Team · Last updated 2026-03-18

Half-life

Buccal absorption within 15-30 minutes; elimination within 30-60 minutes. No formal peer-reviewed PK study with precise half-life measurement identified in English-language literature.

Dosage range

Labor induction: 50 IU buccal every 30 min. Lactation support: 25-50 IU buccal 5 min before feeding

Administration

buccal

Research level

Moderate

How Demoxytocin works

Agonist at oxytocin receptors with greater enzymatic stability than native oxytocin due to the deamino modification at position 1. Promotes rhythmic uterine contractions for labor induction and myoepithelial cell contraction for milk ejection. Buccal absorption enables non-injectable administration.

Also known as: Deamino-oxytocin, ODA-914, 1-Deamino-oxytocin, Sandopart, Odeax, Sandopral

Side effects & safety

Uterine cramping Headache Nausea Hypersensitivity reactions

Contraindications

Cephalopelvic disproportion
Fetal distress
Placenta previa
Prior uterine surgery/cesarean (risk of rupture)
Hypersensitivity to oxytocin analogs

Consult a healthcare provider before use if any of these apply to you.

FAQ

What is Demoxytocin? +
A synthetic oxytocin analog (1-deamino-oxytocin) with N-terminal Cys replaced by β-mercaptopropionic acid (Mpa), conferring greater enzymatic stability. Synthesized 1960, clinically introduced by Sandoz in 1971 as a buccal tablet. Approved in Italy, Czech Republic, and Poland (Sandopart/Odeax/Sandopral) for labor induction and lactation support. Never FDA-approved. Crystal structure solved by Wood et al. (Science 1986, PDB 1XY1/1XY2). Its mechanism of action is supported by moderate clinical and preclinical evidence.
What is Demoxytocin researched for? +
Demoxytocin has the strongest research relevance for . Evidence is supported by moderate clinical and preclinical evidence.
What are the side effects of Demoxytocin? +
Reported side effects include Uterine cramping, Headache, Nausea, Hypersensitivity reactions. Key contraindications: Cephalopelvic disproportion; Fetal distress; Placenta previa; Prior uterine surgery/cesarean (risk of rupture); Hypersensitivity to oxytocin analogs.
Is Demoxytocin FDA approved? +
Demoxytocin is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is Demoxytocin administered? +
Demoxytocin is typically administered via buccal route. Researched dosage range: Labor induction: 50 IU buccal every 30 min. Lactation support: 25-50 IU buccal 5 min before feeding. Half-life: Buccal absorption within 15-30 minutes; elimination within 30-60 minutes. No formal peer-reviewed PK study with precise half-life measurement identified in English-language literature..

Explore similar peptides

AOD-9604

Preliminary evidence

GH Fragment

A modified growth hormone fragment investigated for lipolysis-related effects without full GH receptor profile. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

DSIP

Preliminary evidence

Sleep

An endogenous neuropeptide candidate historically explored for sleep regulation and stress-response modulation. Placed on FDA Category 2 list (September 29, 2023) as 'Emideltide (DSIP).'

Epithalon

Preliminary evidence

Telomere

A synthetic tetrapeptide associated with pineal peptide research and putative telomerase-related aging hypotheses. Placed on FDA Category 2 list (September 29, 2023) as 'Epitalon.'